These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379 [TBL] [Abstract][Full Text] [Related]
6. Investigating the impact of antibiotic-induced dysbiosis on protection from Uddin MJ; Thompson B; Leslie JL; Fishman C; Sol-Church K; Kumar P; Petri WA mBio; 2024 Mar; 15(3):e0333823. PubMed ID: 38376154 [TBL] [Abstract][Full Text] [Related]
7. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence. Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467 [TBL] [Abstract][Full Text] [Related]
8. Plakoglobin and High-Mobility Group Box 1 Mediate Intestinal Epithelial Cell Apoptosis Induced by Clostridioides difficile TcdB. Li Y; Xu W; Ren Y; Cheung HC; Huang P; Kaur G; Kuo CJ; McDonough SP; Fubini SL; Lipkin SM; Deng X; Chang YF; Huang L mBio; 2022 Oct; 13(5):e0184922. PubMed ID: 36043787 [TBL] [Abstract][Full Text] [Related]
9. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil. Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474 [TBL] [Abstract][Full Text] [Related]
10. Intestinal Inflammation and Altered Gut Microbiota Associated with Inflammatory Bowel Disease Render Mice Susceptible to Clostridioides difficile Colonization and Infection. Abernathy-Close L; Barron MR; George JM; Dieterle MG; Vendrov KC; Bergin IL; Young VB mBio; 2021 Jun; 12(3):e0273320. PubMed ID: 34126769 [TBL] [Abstract][Full Text] [Related]
11. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities. Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161 [TBL] [Abstract][Full Text] [Related]
12. Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids. Winston JA; Rivera AJ; Cai J; Thanissery R; Montgomery SA; Patterson AD; Theriot CM Infect Immun; 2020 May; 88(6):. PubMed ID: 32205405 [No Abstract] [Full Text] [Related]
13. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure. Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481 [TBL] [Abstract][Full Text] [Related]
14. Clearance of Clostridioides difficile Colonization Is Associated with Antibiotic-Specific Bacterial Changes. Lesniak NA; Schubert AM; Sinani H; Schloss PD mSphere; 2021 May; 6(3):. PubMed ID: 33952668 [TBL] [Abstract][Full Text] [Related]
15. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Sun X; Hirota SA Mol Immunol; 2015 Feb; 63(2):193-202. PubMed ID: 25242213 [TBL] [Abstract][Full Text] [Related]
16. Epigallocatechin-3-Gallate Improves Intestinal Gut Microbiota Homeostasis and Ameliorates Wu Z; Shen J; Xu Q; Xiang Q; Chen Y; Lv L; Zheng B; Wang Q; Wang S; Li L Nutrients; 2022 Sep; 14(18):. PubMed ID: 36145133 [No Abstract] [Full Text] [Related]
17. Systemic Inflammatory Mediators Are Effective Biomarkers for Predicting Adverse Outcomes in Clostridioides difficile Infection. Dieterle MG; Putler R; Perry DA; Menon A; Abernathy-Close L; Perlman NS; Penkevich A; Standke A; Keidan M; Vendrov KC; Bergin IL; Young VB; Rao K mBio; 2020 May; 11(3):. PubMed ID: 32371595 [No Abstract] [Full Text] [Related]
18. Frontiers in antibiotic alternatives for Phanchana M; Harnvoravongchai P; Wongkuna S; Phetruen T; Phothichaisri W; Panturat S; Pipatthana M; Charoensutthivarakul S; Chankhamhaengdecha S; Janvilisri T World J Gastroenterol; 2021 Nov; 27(42):7210-7232. PubMed ID: 34876784 [No Abstract] [Full Text] [Related]
19. The role of toxins in Clostridium difficile infection. Chandrasekaran R; Lacy DB FEMS Microbiol Rev; 2017 Nov; 41(6):723-750. PubMed ID: 29048477 [TBL] [Abstract][Full Text] [Related]
20. The Gut Bacterial Community Potentiates Clostridioides difficile Infection Severity. Lesniak NA; Schubert AM; Flynn KJ; Leslie JL; Sinani H; Bergin IL; Young VB; Schloss PD mBio; 2022 Aug; 13(4):e0118322. PubMed ID: 35856563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]